^
    Back
    Association details:
    Biomarker:EGFR L858R + HER-2 amplification + PIK3CA overexpression
    Cancer:Lung Cancer
    Drug:gefitinib (EGFR inhibitor) +
    Piqray (alpelisib) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    BMC Cancer
    Title:

    BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells

    Published date:
    08/08/2023
    Excerpt:
    ...we also used H1975 and H1650 lung cancer cells to evaluate the synergetic effects of gefitinib and BYL719. The H1975 cells harbored EGFR L858R mutation with ErBb2 amplification...The over-expression of PIK3CA was also confirmed in H1975 and H1650 cells...EdU assay showed that proliferation rates of cells in combination group were also significantly lower than those in gefitinib group or BYL719 group in the PC-9-PIK3CA-M and H1975 cells (Fig. 3C, P < 0.05).
    DOI:
    https://doi.org/10.1186/s12885-023-11243-0